2018
A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan
Lee V, Wang J, Zahurak M, Gootjes E, Verheul H, Parkinson R, Kerner Z, Sharma A, Rosner G, De Jesus-Acosta A, Laheru D, Le DT, Oganesian A, Lilly E, Brown T, Jones P, Baylin S, Ahuja N, Azad N. A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan. Clinical Cancer Research 2018, 24: 6160-6167. PMID: 30097434, DOI: 10.1158/1078-0432.ccr-18-0421.Peer-Reviewed Original ResearchConceptsMetastatic colorectal cancerNeutropenic feverMetastatic colorectal cancer patientsDurable partial responseMost common toxicitiesDose-escalation studyColorectal cancer patientsInjection site reactionsOngoing phase IIPhase I trialInitial disease progressionCycles of treatmentCommon toxicitiesDrain infectionEvaluable patientsStable diseaseColonic obstructionPartial responseI trialMulticenter trialColorectal cancerGastrointestinal cancerSite reactionsCancer patientsDisease progressionComparing the long‐term outcomes among patients with stomach and small intestine gastrointestinal stromal tumors: An analysis of the National Cancer Database
Giuliano K, Ejaz A, Reames BN, Choi W, Sham J, Gage M, Johnston FM, Ahuja N. Comparing the long‐term outcomes among patients with stomach and small intestine gastrointestinal stromal tumors: An analysis of the National Cancer Database. Journal Of Surgical Oncology 2018, 118: 486-492. PMID: 30129672, DOI: 10.1002/jso.25172.Peer-Reviewed Original ResearchConceptsSmall intestine gastrointestinal stromal tumorGastrointestinal stromal tumorsNational Cancer DatabaseOverall survivalStromal tumorsTumor locationCancer DatabaseLarger median tumor sizeStomach gastrointestinal stromal tumorUnadjusted median overall survivalCox proportional hazards modelNational Oncology DatabaseMedian overall survivalMedian tumor sizeWorse prognostic featuresKaplan-Meier methodLong-term prognosisTumor-related factorsLong-term outcomesCases of stomachProportional hazards modelCommon sarcomaTotal patientsPrognostic featuresOncology databaseMinimally Invasive Versus Open Primary Resection for Retroperitoneal Soft Tissue Sarcoma: A Propensity-Matched Study From the National Cancer Database
Gani F, Goel U, Blair AB, Singh J, Overton HN, Meyer CF, Canner JK, Pawlik TM, Ahuja N, Johnston FM. Minimally Invasive Versus Open Primary Resection for Retroperitoneal Soft Tissue Sarcoma: A Propensity-Matched Study From the National Cancer Database. Annals Of Surgical Oncology 2018, 25: 2209-2217. PMID: 29855832, PMCID: PMC8383095, DOI: 10.1245/s10434-018-6538-y.Peer-Reviewed Original ResearchConceptsRetroperitoneal soft tissue sarcomaNational Cancer DatabaseSoft tissue sarcomasUse of MISPostoperative mortalityPrimary resectionOverall survivalClinical outcomesTissue sarcomasCancer DatabaseCox proportional hazards modelShorter hospital lengthProportional hazards modelHospital lengthInvasive VersusMultivariable logisticPelvic cancerShorter LOSOpen surgeryOperative approachCommunity hospitalInclusion criteriaSmall tumorsTreatment groupsHazards model
2017
Differential expression of hENT1 and hENT2 in colon cancer cell lines
Liu Y, Zuo T, Zhu X, Ahuja N, Fu T. Differential expression of hENT1 and hENT2 in colon cancer cell lines. Genetics And Molecular Research 2017, 16 PMID: 28218790, DOI: 10.4238/gmr16019549.Peer-Reviewed Original ResearchConceptsColon cancer cell linesCancer cell linesMetastatic CRCColorectal cancerHENT1 expressionCell linesHigh hENT1 expressionLow hENT1 expressionMetastatic colorectal cancerNucleoside analoguesHuman equilibrative nucleoside transporter 1Equilibrative nucleoside transporter 1Real-time polymerase chain reactionDrug-based treatmentQuantitative real-time polymerase chain reactionHuman colon cancer cell linesNucleoside transporter 1Clinical responseMost patientsMetastatic cell linesMetastatic sitesMetastatic tumorsTransporter expression profilesPolymerase chain reactionDifferent drug responses
2014
Clinicopathologic Presentation and Natural History of Anorectal Melanoma: A Case Series of 18 Patients
Hicks CW, Pappou EP, Magruder JT, Gazer B, Fang S, Wick EC, Gearhart SL, Ahuja N, Efron JE. Clinicopathologic Presentation and Natural History of Anorectal Melanoma: A Case Series of 18 Patients. JAMA Surgery 2014, 149: 608-611. PMID: 24848283, DOI: 10.1001/jamasurg.2013.4643.Peer-Reviewed Original ResearchConceptsAnorectal melanomaOverall disease-specific mortalityNatural historyDisease-specific mortalityDisease-specific survivalNonspecific presenting symptomsWide local excisionRare malignant neoplasmVariable natural historyNonspecific presentationPresenting symptomAbdominoperineal resectionLocal excisionCase seriesMedian timeSurgical managementRectal lesionsMalignant neoplasmsPrognostic parametersClinicopathologic presentationLate diagnosisAdvanced stageIncorrect diagnosisSmall lesionsLarger study
2011
Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis
Fang F, Turcan S, Rimner A, Kaufman A, Giri D, Morris LG, Shen R, Seshan V, Mo Q, Heguy A, Baylin SB, Ahuja N, Viale A, Massague J, Norton L, Vahdat LT, Moynahan ME, Chan TA. Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis. Science Translational Medicine 2011, 3: 75ra25. PMID: 21430268, PMCID: PMC3146366, DOI: 10.1126/scitranslmed.3001875.Peer-Reviewed Original ResearchConceptsGenome-wide analysisBreast cancer methylomeBreast cancer epigenomeDistinct epigenomic profilesCancer-specific alterationsMetastatic behaviorHuman malignanciesCancer methylomeCancer epigenomeEpigenomic contributionEpigenomic profilesDNA methylationTranscriptomic changesHypermethylator phenotypeMultiple human malignanciesCpG island methylator phenotypeBreast cancer oncogenesisGenesCancer oncogenesisMethylomeMethylationLociLow metastatic riskMetastatic potentialMethylator phenotype